{
    "clinical_study": {
        "@rank": "129325", 
        "arm_group": [
            {
                "arm_group_label": "Usual care group", 
                "arm_group_type": "Active Comparator", 
                "description": "Usual care"
            }, 
            {
                "arm_group_label": "Intensive care group", 
                "arm_group_type": "Active Comparator", 
                "description": "Protocolized intensive treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the effectiveness of two treatment strategies in early rheumatoid arthritis\n      (ERA), namely the delayed usual care and early intensive care, in Hong Kong.\n\n        -  The delayed usual care reflects the usual treatment practice in Hong Kong\n\n        -  The early intensive care includes tight monitoring and immediate adjustment of therapy"
        }, 
        "brief_title": "Early RA MRI Early Intensive Treatment Study", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Early Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a 1-year  non-randomized clinical trial. Two groups of patients (delayed usual\n      care and early intensive care) with diagnosis of rheumatoid arthritis (RA) and with symptoms\n      onset of less than 2 years and disease modifying anti-rheumatic drugs (DMARDs) naive will be\n      recruited. Remission is reached if patients fulfill the Boolean criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For usual care group:\n\n          -  patients with at least 1 tender and swollen joint\n\n          -  duration of symptoms less than 2 years\n\n          -  no previous use of DMARDs\n\n        For intensive care group:\n\n          -  patients with at least 1 tender and swollen joint\n\n          -  duration of symptoms less than 2 years\n\n          -  no previous use of DMARDs\n\n          -  patients who fulfill the 2010 ACR/EULAR classification criteria for RA\n\n        Exclusion Criteria:\n\n          -  patients with renal impairment (on dialysis or estimated Glomerular Filtration Rate\n             (eGFR) <30 mL/min/1.73m^2)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762176", 
            "org_study_id": "ERA-MRI-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intensive care group", 
                "description": "Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol", 
                "intervention_name": "Protocolized intensive treatment", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Usual care group", 
                "description": "Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice", 
                "intervention_name": "Usual care", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Early Rheumatoid Arthritis", 
            "Usual care", 
            "Intensive Care", 
            "Boolean criteria"
        ], 
        "lastchanged_date": "January 14, 2013", 
        "location": {
            "contact": {
                "email": "lstam@cuhk.edu.hk", 
                "last_name": "Lai Shan Tam, MD", 
                "phone": "00852-2632 3996"
            }, 
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "China"
                }, 
                "name": "Prince of Wales Hospital"
            }, 
            "investigator": {
                "last_name": "Lai Shan Tam, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Early Intensive Treatment in Chinese Patients With Recent-onset Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "lstam@cuhk.edu.hk", 
            "last_name": "Lai Shan Tam, MD", 
            "phone": "00852-2632 3996"
        }, 
        "overall_official": {
            "affiliation": "Chinese University of Hong Kong", 
            "last_name": "Lai Shan Tam, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The clinical remission is defined using the latest ACR/EULAR remission criteria (Boolean criteria)", 
            "measure": "The proportion of patients who achieve clinical remission", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762176"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese University of Hong Kong", 
            "investigator_full_name": "Lai-Shan Tam", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The various patient-reported outcomes include employment status, Working Ability Index (WAI), disability index of Health Assessment Questionnaire (HAQ), Functional Assessment of Chronic Illness Therapy (FACIT), Hospital Anxiety and Depression Scale (HADS) and Health-related quality of life (HRQoL) generic measures", 
                "measure": "Change in various patient-reported outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The Utility score is calculated by EQ-5D self-report questionnaire, which provides a single index value for health status that can be used in the clinical and economic appraisal. Value set derived from a Chinese cohort in Beijing is used, since no value set for Hong Kong Chinese population is available.", 
                "measure": "Gains in utility", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Radiographic progression expressed using the van der Hejide modification of the Sharp scored", 
                "measure": "Radiographic progression", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The ACR 20, 50, 70 responses are defined as at least 20%, 50%, 70% improvement in joint swelling and joint tenderness counts, and at least three of five other variables (i.e. erythrocyte sedimentation rate, HAQ score, pain score, and physicians' and patients' global assessments)", 
                "measure": "ACR 20, 50, 70 responses", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "MRI image set is evaluated and scored separately for the presence or absence of MRI erosion, synovitis, and bone marrow oedema. Bone erosions and bone marrow oedema are evaluated separately in each wrist bone, whereas synovitis is evaluated in the three regions of the wrist joint: the radioulnar area, the radiocarpal area, and the intercarpal-carpometacarpal area.", 
                "measure": "MRI outcome", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Chinese University of Hong Kong", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese University of Hong Kong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}